Benefits and risks of hormonal replacement therapy - An update;Nutzen und risiko der hormonersatztherapie - Ein update

Gynakologisch-geburtshilfliche Rundschau

Volumn 46, Issue 4, 2006, Pages 166-173

  Schmidt, Markus ^a   Kimmig, R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Estrogen; Gestagen; Hormonal replacement therapy, risk benefit; Menopause

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEGESTROL; MEGESTROL ACETATE; NORETHISTERONE; RALOXIFENE; VITAMIN D;

BREAST CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; HORMONE SUBSTITUTION; HUMAN; MEDICAL PRACTICE; MENOPAUSAL SYNDROME; META ANALYSIS; OSTEOPOROSIS; OVARY CARCINOMA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; URINARY TRACT INFECTION; UROGENITAL TRACT MALFORMATION;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COLONIC NEOPLASMS; DEMENTIA; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; META-ANALYSIS; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIAN NEOPLASMS; PRIMARY PREVENTION; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RISK; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS;

EID: 33750442516     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095725     Document Type: Review

References (84)

1. Speroff L, Glass R, Kase N: Clinical Gynecological Endocrinology and Infertility. Baltimore, Lippincott, Williams & Wilkins, 1999.
2. Goldzieher W: Historical perspectives; in Lobo R, Kesley J, Marcus R (Hrsg): Menopause: Biology and Pathobiology. San Diego, Academic Press, 2000, pp 397-404.
3. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens C: Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
4. Stampfer MJ, Colditz GA, Willert WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
5. Paganini Hill A, Henderson VW: Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-2217.
6. Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
7. Chute CG, Willett WC, Colditz GA, Stampfer MJ, Rosner B, Speizer FE: A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology 1991;2:201-207.
8. Henderson BE, Paganini Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.
9. Schneider H: The view of the International Menopause society on the Women's Health Initiative. Climacteric 2002;5:11-16.
10. MacLennan AH, Lester S, Moore V: Oral estrogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2002;1:CD002978.
11. Dennerstein L, Burrows GD, Hyman G, Wood C: Menopausal hot flushes: a double-blind comparison of placebo, ethinyl oestradiol and norgestrel. Br J Obstet Gynaecol 1978;85:852-856.
12. Schiff I, Tulchinsky D, Cramer D, Ryan KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445.
13. Aslaksen K, Frankendal B: Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1982;61:423-428.
14. Morrison JC, Martin DC, Blair RA, Anderson GD, Kincheloe BW, Bates GW, Hendrix JW, Rivlin ME, Forman EK, Propst MG, Needham R: The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
15. Paterson M: A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1982;89:464-472.
16. Farish E, Barnes JF, O'Donoghue F, Fletcher CD, Ekevall K, Hart DM: The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric 2000;3:125-134.
17. Bachmann GA: A new option for managing urogenital atrophy in postmenopausal women. Contemp Obstet Gynecol 1997;42:13-28.
18. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E: Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-297.
19. Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B: Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 2001;98:1045-1052.
20. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L: Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727.
21. Grodstein F, Lifford K, Resnick NM, Curhan GC: Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004;103:254-260.
22. Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risk and benefits of estrogen plus progestin therapy in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:312-333.
23. Anderson Gl, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, La Croix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawaski-Wende J, Wallace R, Wassertheil-Smoller S: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
24. Kanis JA: Diagnosis of osteoporosis. Osteoporos Int 1997;7:108-116.
25. Henry D, Robertson J, O'Connell D, Gillespie W: A systematic review of the skeletal effects of estrogen therapy in postmenopausal women: an assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998;1:92-111.
26. Cummings SR, Black D, Rubin S: Life time risk of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-2448.
27. Felson D, Zhang Y, Hannan M: The effect of postmenopausal oestrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-1146.
28. Critchley H, Gebbie A, Beral V: Menopause and hormone replacement. Proc 47th RCOG Study Group, London, 2004.
29. Andrews H, Christie B, Colledge N, Gallacher S, Glasier A, MacDonald J: Consensus statement. J R Coll Physicians Edinb 2004;34:2-3.
30. AWMF online: Leitlinie Osteologie - Empfehlungen des Dachverbandes der deutschsprachigen osteologischen Fachgesellschaften (DVO): Osteoporose bei postmenopausalen Frauen 2003.
31. Gass M, Dawson-Hughes B: Preventing osteoporosis-related fractures: an overview. Am J Med 2006;119:3-11.
32. Rabe T, Geisthövel F, Bock K, Deckner C, Mueck AO: Hormonersatztherapie - Nutzen und Risiken. J Reproduktionsmed Endokrinol 2004;1:77-81.
33. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJ: Postmenopausal hormone use and risk for colorectal cancer and adenome. Ann Intern Med 1998;128:705-712.
34. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517-523.
35. Hickey M, Davis SR, Sturdee DW: Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409-421.
36. McBee WL, Dailes ME, Dugan E, Shumaker SA: Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am 1997;26:329-345.
37. Carlson MC, Zandi PP, Plassman BL, Tschanz JT, Welsh-Bohmer KA, Steffens DC, Bastian LA, Mehta KM, Breitner JC, Cache County Study Group: Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 2001;57:2210-2216.
38. Lokkegaard E, Pedersen AT, Laursen P, Loft IP, Larsen S, Jorgensen T: The influence of hormone replacement therapy on the aging-related change in cognitive performance: analysis based on a Danish cohort study. Maturitas 2002;42:209-218.
39. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
40. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J: Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:3005-3007.
41. Colditz GA, Hankinson SE, Hunter DJ, Willeth WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
42. Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
43. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
44. Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
45. Spratt JS, Meyer JS, Spratt JA: Rates of growth of human neoplasms. Part 1. J Surg Oncol 1995;60:137-146.
46. Dietel M, Lewis MA, Shapiro S: Mini review: hormone replacement therapy: pathophysiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT. Hum Reprod 2000;20:2052-2060.
47. Davis SR, Dinatale I, Rivers-Wol L, Davison S: Postmenopausal hormone therapy: from monkey glands to transdermal patches. J Endocrinol 2005;185:207-222.
48. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253.
49. Horwitz R, Feinstein AR: Alternative analytic methods for case control studies of oestrogens and endometrial cancer. N Engl J Med 1978;299:1089-1094.
50. Antunes CMF, Stolley PD, Rosenstein MB: Endometrial cancer and oestrogen use: report of a large case-control study. N Engl J Med 1979;300:9-13.
51. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A: The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-756.
52. Paganini-Hill RR, Henderson BE: Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445-447.
53. Green PK, Weiss NS, McKnight B: Risk of endometrial cancer following cessation of menopausal hormone use. Cancer Causes Control 1996;7:575-580.
54. DGGG: Konsensusempfehlungen zur Hormontherapie (HRT) im Klimakterium und in der Postmenopause. Frauenarzt 2004;45:620-627.
55. Emons G, Huschmand-Nia A, Krauss T, Hinney B: Hormone replacement therapy and endometrial cancer. Onkologie 2004;27:207-210.
56. Million Women Study Collaborators: Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551.
57. Emons G: Sind Östrogene Karzinogene? Frauenarzt 2006;47:430-435.
58. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hauuninghake D: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
59. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.
60. Lacey J, Mink P, Lubin J, Sherman M, Troisi R, Hartge P, Schatzkin A, Schairer C: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-337.
61. Miller J, Chan BK, Nelson HD: Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002;136:680-690.
62. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
63. Warren MP: A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 2004;190:1141-1167.
64. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-1249.
65. Hernandez AM, Walker AM, Jick H: Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1990;1:128-133.
66. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
67. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
68. Humphrey LL, Chan BKS, Sox HC: Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:237-284.
69. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
70. Clarke SC, Keleher J, Lloyd-Jones H, Slack M, Schofield PM: A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002;109:1056-1062.
71. ESPRIT team: Oestrogen therapy for the prevention of reinfarction in postmenopausal women: a randomised placebo-controlled trial. Lancet 2002;360:2001-2008.
72. Grodstein F, Manson JE, Stampfer MJ: Hormone therapy and coronary heart disease: the role of time since menopause and age of hormone initiation. J Women's Health 2006;15:35-44.
73. Mueck AO: HRT und Herzinfarkte: Prävention bei frühem Beginn nachgewiesen. Frauenarzt 2006;47:421-430.
74. Völker W, Coelingh Bennink HJ, Helmond FA: Effects of tibolone on the endometrium. Climacteric 2001;4:203-208.
75. Wender MC, Edelweiss MI, Campos LS, de Castro JA, Spritzer PM: Endometrial assessment in women using tibolone or placebo: 1-year randomised trial and 2-year observational study. Menopause 2004;11:423-429.
76. Hammar M, Christau S, Nathoorst-Boos J, Rud T, Garre K: A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904-911.
77. Morris E, Wilson P, Robinson J, Rymer J: Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999;106:954-959.
78. Landgren BM, Bennink HJ, Helmond FA, Engelen S: Dose-response analysis of effects of tibolone on climacteric symptoms. Br J Obstet Gynaecol 2002;109:1109-1114.
79. Egarter C, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F, Putz M: Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996;23:55-62.
80. Bruce D, Robinson J, Rymer J: Long-term-effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 2004;7:261-266.
81. Grobbee DE: LIFT study to continue as planned. BMJ 2005;331:843.
82. Cummings SR: LIFT study is discontinued. BMJ 2006;332:67.
83. Palomba S, Di Carlo C, Morelli M, Ruso T, Noia R, Nappi C, Mastrantonio P, Zullo F: Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy. Maturitas 2003;45:267-273.
84. Valdivia I, Campodonic I, Tapia A, Capetillo M, Espinoza A, Lavin P: Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617-623.